Revenue Expected to Exceed $18 Million for 2012 Fourth Quarter
January 07 2013 - 8:30AM
Marketwired
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser
manufacturer and distributor, announced today that, based on a
preliminary review of its financial performance for the fourth
quarter ended December 31, 2012, the Company expects to exceed its
previous guidance and report net revenue in excess of $18 million.
Federico Pignatelli, Chairman and CEO of BIOLASE, said, "We are
very pleased with the strong growth in our core dental laser
products and the trends that are accelerating with the adoption of
our WaterLase® technology and diode laser systems. Our strong
revenue growth in the 2012 fourth quarter compared to the prior
year period was primarily due to the increased demand for our
flagship WaterLase iPlus™ and our new EPIC 10™ soft tissue diode
laser. Revenues were also bolstered by sales of our mid-priced
WaterLase products and our digital imaging products, including the
initial sales of our CAD/CAM systems."
"After closing 2012 on a strong note, we are very excited to
look ahead to 2013 and beyond as we expect a substantial
acceleration in the adoption of lasers, specifically our core
WaterLase technology, in dental practices around the world over the
next three to five years. We are very confident that all-tissue
lasers will become the standard of care in dental practices
worldwide. Furthermore, as we move forward in 2013 we do not expect
to be troubled with the multitude of extraneous issues that we
faced throughout our challenging turnaround, including exiting our
exclusive global distribution relationship with Henry Schein, Inc.
(NASDAQ: HSIC), and moving to a direct sales model in North America
and multi-distributor model internationally," concluded
Pignatelli.
About WaterLase BIOLASE's patented WaterLase technology combines
its proprietary 2,780nm YSGG laser energy, air, and water that all
emanate from its patented hand piece to symbiotically excite water
molecules from within both the spray and the target tissue. This
results in a biological ablation of both hard- and soft-tissue.
Currently, BIOLASE offers several variations of WaterLase laser
systems, including the flagship iPlus, the mid-priced MDX™ 450 and
300, and certified pre-owned MD Turbos™.
About BIOLASE, Inc. BIOLASE, Inc. is a biomedical company that
develops, manufactures and markets dental lasers and also
distributes and markets dental imaging equipment; products that are
focused on technologies that advance the practice of dentistry and
medicine. The Company's laser products incorporate approximately
290 patented and patent-pending technologies designed to provide
biological treatment and clinically superior performance with less
pain and faster recovery times. Its imaging products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
dental laser systems that perform a broad range of dental
procedures, including cosmetic and complex surgical applications,
and a full line of dental imaging equipment and CAD/CAM systems.
BIOLASE has sold more than 21,000 lasers. Other products under
development address ophthalmology and other medical and consumer
markets.
For updates and information on WaterLase and laser dentistry,
find BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and
YouTube at www.youtube.com/biolasevideos.
Add to Digg Bookmark with del.icio.us Add to Newsvine
For further information, please contact: Lisa Wilson In-Site
Communications, Inc. 212-759-3929
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Apr 2024 to May 2024
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From May 2023 to May 2024